RIGEL PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
RIGEL PHARMACEUTICALS, INC. (RIGL) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $32.52 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $32.52M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $95.28M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $7.96M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $36.41M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $32.52M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $95.28M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $7.96M 10-K · filed 2026-03-03 |
| 2025-09-30 | $36.41M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $43.42M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $20.27M 10-Q · filed 2025-05-06 |
| 2024-06-30 | $22.96M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $27.99M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $10.54M 10-K · filed 2024-03-05 |
| 2023-09-30 | $19.18M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $18.53M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $17.87M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $46.31M 10-K · filed 2023-03-07 |
| 2022-09-30 | $60.19M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $67.46M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $90.34M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $88.04M 10-K · filed 2022-03-01 |
| 2021-09-30 | $38.49M 10-Q · filed 2021-11-02 |
| 2020-12-31 | $23.69M 10-K · filed 2021-03-02 |
| 2020-09-30 | $14.03M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $19.55M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $13.66M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $31.25M 10-K · filed 2020-02-27 |
| 2019-09-30 | $21.96M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $43.28M 10-Q · filed 2019-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |